Aligos Therapeutics
ALGS
45 hedge funds and large institutions have $23.9M invested in Aligos Therapeutics in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
18% more funds holding
Funds holding: 38 → 45 (+7)
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
0.08% more ownership
Funds ownership: 2.67% → 2.75% (+0.08%)
5% less capital invested
Capital invested by funds: $25.3M → $23.9M (-$1.35M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$1.53M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$966K |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$930K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$352K |
| 5 |
Morgan Stanley
New York
|
+$199K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.38M |
| 2 |
NM
Newtyn Management
New York
|
-$731K |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$382K |
| 4 |
NYLIM
New York Life Investment Management
New York
|
-$251K |
| 5 |
Renaissance Technologies
New York
|
-$121K |
ALGS Hedge Fund Activity: Q1 2023 in Review
45 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q1 2023, worth a combined $23.9M — down 5.4% from $25.3M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ALGS positions and 3 closed out — a net gain of 7 holders — while 11 added to existing stakes and 10 trimmed.
The largest buyer was Logos Global Management, opening a new position worth an estimated $1.53M. The largest seller was Point72 Asset Management, cutting an estimated $1.38M.
- 45 institutional investors held Aligos Therapeutics (ALGS) as of Q1 2023, up from 38 in Q4 2022.
- Funds reported $23.9M of Aligos Therapeutics stock for Q1 2023, down 5.4% quarter-over-quarter.
- 10 funds opened new Aligos Therapeutics positions in Q1 2023 and 3 closed out, a net change of +7 holders.
- The largest Aligos Therapeutics buyer in Q1 2023 was Logos Global Management, an estimated $1.53M added.
- The largest Aligos Therapeutics seller in Q1 2023 was Point72 Asset Management, an estimated $1.38M sold.
Based on aggregated 13F filings for Q1 2023.